Los Angeles Capital Management
FOLD

Los Angeles Capital Management’s Amicus Therapeutics FOLD Stock Holding History

Los Angeles Capital Management’s Portfolio FOLD Stock Details FOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$18.1K Sell
1,252
-75,372
-98% -$1.08M ﹤0.01% 1769
2025
Q4 		$682K Buy
76,624
+24,151
+46% +$237K ﹤0.01% 776
2025
Q3 		$413K Buy
+52,473
New +$373K ﹤0.01% 1001
2025
Q2 		– Sell
-20,504
Closed -$167K – 1382
2025
Q1 		$167K Buy
20,504
+30
+0.1% +$278 ﹤0.01% 1047
2024
Q4 		$193K Hold
20,474
– – ﹤0.01% 1060
2024
Q3 		$219K Buy
20,474
+6,484
+46% +$70.6K ﹤0.01% 1103
2024
Q2 		$139K Sell
13,990
-104,370
-88% -$1.07M ﹤0.01% 1142
2024
Q1 		$1.39M Buy
118,360
+105,384
+812% +$1.35M ﹤0.01% 585
2023
Q4 		$184K Hold
12,976
– – ﹤0.01% 1102
2023
Q3 		$158K Buy
+12,976
New +$167K ﹤0.01% 1079
2021
Q3 		– Sell
-42,422
Closed -$409K – 1515
2021
Q2 		$409K Sell
42,422
-76,582
-64% -$748K ﹤0.01% 1262
2021
Q1 		$1.18M Sell
119,004
-28,936
-20% -$448K 0.01% 819
2020
Q4 		$3.42M Sell
147,940
-8,010
-5% -$164K 0.01% 496
2020
Q3 		$2.2M Sell
155,950
-69,715
-31% -$1.02M 0.01% 542
2020
Q2 		$3.4M Buy
225,665
+1,022
+0.5% +$12.5K 0.02% 483
2020
Q1 		$2.08M Buy
224,643
+105,339
+88% +$1M 0.01% 525
2019
Q4 		$1.16M Buy
119,304
+97,980
+459% +$897K 0.01% 795
2019
Q3 		$171K Sell
21,324
-79,706
-79% -$865K ﹤0.01% 1220
2019
Q2 		$1.26M Buy
101,030
+5,915
+6% +$75.1K 0.01% 771
2019
Q1 		$1.29M Buy
95,115
+65,750
+224% +$803K 0.01% 771
2018
Q4 		$281K Sell
29,365
-16,550
-36% -$182K ﹤0.01% 1125
2018
Q3 		$555K Sell
45,915
-1,830
-4% -$25.6K ﹤0.01% 1073
2018
Q2 		$746K Buy
47,745
+6,420
+16% +$97.1K ﹤0.01% 1019
2018
Q1 		$622K Buy
+41,325
New +$629K ﹤0.01% 967

Other funds holding FOLD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Los Angeles Capital Management's FOLD Position: Q1 2026 in Review

Los Angeles Capital Management reduced its Amicus Therapeutics (FOLD) stake by 98% in Q1 2026, selling an estimated $1.08M and leaving 1,252 shares worth $18.1K. The position accounts for ﹤0.01% of the portfolio, ranked #1769.

Los Angeles Capital Management first reported a position in FOLD in Q1 2018 and has held it in 24 quarters since. The position peaked at $3.42M in Q4 2020. 298 funds tracked by Wall St. Rank hold FOLD as of Q1 2026.

  • Los Angeles Capital Management held 1,252 shares of Amicus Therapeutics worth $18.1K as of Q1 2026.
  • Los Angeles Capital Management sold 75,372 Amicus Therapeutics shares in Q1 2026, an estimated $1.08M.
  • Amicus Therapeutics made up ﹤0.01% of Los Angeles Capital Management's portfolio in Q1 2026, its #1769 holding.
  • Los Angeles Capital Management first reported a position in Amicus Therapeutics in Q1 2018 and has held it in 24 quarters since.
  • Los Angeles Capital Management's Amicus Therapeutics position peaked at $3.42M in Q4 2020.
  • 298 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q1 2026.

Based on Los Angeles Capital Management's 13F filing for Q1 2026, filed 8 May 2026.